Genfit S.A.(GNFT)Earnings, Financials & Key Ratios
GNFT•NASDAQ
$8.95
$448M mkt cap·256.9× P/E·Price updated Apr 24, 2026
AboutGenfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.Show more
- Revenue$67M+134.6%
- EBITDA$5M+120.1%
- Net Income$2M+105.2%
- EPS (Diluted)0.03+105.2%
- Gross Margin99.55%+0.8%
- EBITDA Margin7.47%+108.6%
- Operating Margin4.9%+105.3%
- Net Margin2.25%+102.2%
- ROE2.2%+106.2%
- ROIC4.48%+110.6%
- Debt/Equity0.90-13.1%
- Interest Coverage1.38+126.9%
GNFT Key Insights
Genfit S.A. (GNFT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓FCF machine: 21.2% free cash flow margin
- ✓Momentum leader: RS Rating 96 (top 4%)
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 16.8%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
GNFT Price & Volume
Genfit S.A. (GNFT) stock price & volume — 10-year historical chart
Loading chart...
GNFT Growth Metrics
Genfit S.A. (GNFT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years45.15%
5 Years16.79%
3 Years-5.77%
TTM9.75%
Profit CAGR
10 Years-
5 Years-
3 Years-71.81%
TTM-161.19%
EPS CAGR
10 Years-
5 Years-
3 Years-71%
TTM-212.82%
Return on Capital
10 Years-19.12%
5 Years-9.9%
3 Years-9.26%
Last Year3.1%
GNFT Recent Earnings
Genfit S.A. (GNFT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (50%)●Beat Revenue 6/12 qtrs (75%)
Q2 2025Latest
May 22, 2025EPS
$0.64
Est $0.26
-148.9%
Revenue
$11M
Est $30M
-62.6%
Q4 2024
Sep 19, 2024EPS
$0.54
Est $0.33
+62.3%
Revenue
$66M
Est $51M
+28.9%
Q4 2023
Dec 30, 2023EPS
$0.18
Revenue
$19M
Q4 2023
Sep 20, 2023EPS
$0.45
Est $0.32
-41.1%
Revenue
$16M
Est $15M
+5.8%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2025Latest | May 22, 2025 | $0.64vs $0.26-148.9% | $11Mvs $30M-62.6% |
| Q4 2024 | Sep 19, 2024 | $0.54vs $0.33+62.3% | $66Mvs $51M+28.9% |
| Q4 2023 | Dec 30, 2023 | $0.18 | $19M |
| Q4 2023 | Sep 20, 2023 | $0.45vs $0.32-41.1% | $16Mvs $15M+5.8% |
Based on last 12 quarters of dataView full earnings history →
GNFT Peer Comparison
Genfit S.A. (GNFT) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MDGL | 12.27B | 534.86 | -41.62 | 432.05% | -27.32% | -50.15% | 0.59 | |
 AKRO | 4.5B | 54.65 | -14.57 | -30.58% | 0.05 | |||
 HALO | 7.68B | 65.19 | 25.46 | 37.55% | 22.69% | 6.49% | ||
 ELVN | 2.39B | 40.29 | -22.02 | -24.22% | ||||
 ALDX | 104.08M | 1.73 | -1.84 | -87.71% | 0.22 | |||
 CRNX | 4.55B | 43.48 | -8.78 | 6.41% | -31.43% | -43.96% | 0.05 | |
 ARWR | 10.92B | 77.95 | -6389.34 | 232.58% | -48.38% | -55.47% | 0.73 | |
 ALNY | 39.48B | 295.91 | 127 | 65.19% | 13.46% | 98.29% | 1.62 |
Compare GNFT vs Peers
Genfit S.A. (GNFT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GNFT Income Statement
Genfit S.A. (GNFT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 284K | 118K | 69K | 30.84M | 765K | 80.07M | 20.2M | 28.57M | 67M | 116.8M |
| Revenue Growth % | -46.11% | -58.45% | -41.53% | 44594.2% | -97.52% | 10366.54% | -74.78% | 41.45% | 134.56% | 9.75% |
| Cost of Goods Sold | 1.99M | 2.23M | 1.85M | 177K | 202K | 161K | 248K | 341K | 300K | -4.71M |
| COGS % of Revenue | 698.94% | 1888.98% | 2686.96% | 0.57% | 26.41% | 0.2% | 1.23% | 1.19% | 0.45% | - |
| Gross Profit | -1.7M▲ 0% | -2.11M▼ 24.1% | -1.78M▲ 15.4% | 30.66M▲ 1817.8% | 563K▼ 98.2% | 79.91M▲ 14093.3% | 19.95M▼ 75.0% | 28.22M▲ 41.5% | 66.7M▲ 136.3% | 122.47M▲ 0% |
| Gross Margin % | -598.94% | -1788.98% | -2586.96% | 99.43% | 73.59% | 99.8% | 98.77% | 98.81% | 99.55% | 104.85% |
| Gross Profit Growth % | -21.15% | -24.1% | 15.44% | 1817.76% | -98.16% | 14093.25% | -75.04% | 41.49% | 136.33% | - |
| Operating Expenses | 32.46M | 54.58M | 67.7M | 88.67M | 78.35M | 53.54M | 47.5M | 54.8M | 63.42M | 129.52M |
| OpEx % of Revenue | 11428.17% | 46256.78% | 98115.94% | 287.53% | 10242.35% | 66.87% | 235.19% | 191.86% | 94.66% | - |
| Selling, General & Admin | 11.65M | 13.41M | 4.5M | 30.97M | 25.49M | 17.69M | 17.4M | 8.04M | 20.13M | 38.63M |
| SG&A % of Revenue | 4103.87% | 11361.02% | 6514.49% | 100.43% | 3331.5% | 22.1% | 86.15% | 28.15% | 30.05% | - |
| Research & Development | 19.19M | 35.09M | 47.66M | 66.17M | 59.1M | 35.17M | 35.82M | 46.71M | 47.21M | 74.44M |
| R&D % of Revenue | 6755.99% | 29741.53% | 69073.91% | 214.57% | 7725.1% | 43.92% | 177.36% | 163.52% | 70.46% | - |
| Other Operating Expenses | 1.61M | 6.08M | 6.41M | -8.47M | -6.23M | 682K | -5.72M | 53K | -3.92M | -79K |
| Operating Income | -34.16M▲ 0% | -56.7M▼ 66.0% | -69.48M▼ 22.6% | -57.83M▲ 16.8% | -82.9M▼ 43.3% | 31.82M▲ 138.4% | -27.29M▼ 185.8% | -26.58M▲ 2.6% | 3.28M▲ 112.3% | 517K▲ 0% |
| Operating Margin % | -12027.46% | -48046.61% | -100701.45% | -187.53% | -10836.21% | 39.74% | -135.13% | -93.05% | 4.9% | 0.44% |
| Operating Income Growth % | -93.25% | -65.98% | -22.56% | 16.77% | -43.34% | 138.38% | -185.77% | 2.6% | 112.34% | - |
| EBITDA | -33.36M | -55.16M | -68.05M | -52.58M | -79.34M | 34.56M | -25.46M | -24.93M | 5M | 3.89M |
| EBITDA Margin % | -11746.13% | -46748.31% | -98621.74% | -170.5% | -10370.98% | 43.16% | -126.06% | -87.26% | 7.47% | 3.33% |
| EBITDA Growth % | -92.28% | -65.36% | -23.36% | 22.73% | -50.89% | 143.56% | -173.66% | 2.09% | 120.08% | -80.99% |
| D&A (Non-Cash Add-back) | 799K | 1.53M | 1.44M | 5.25M | 3.56M | 2.74M | 1.83M | 1.65M | 1.72M | 3.37M |
| EBIT | -34.16M | -56.69M | -69.53M | -54.28M | -76.58M | 32.16M | -27.64M | -23.89M | 6.62M | -4.76M |
| Net Interest Income | 193K | -1.94M | -10.79M | -8.83M | -10.35M | -4.68M | -4.27M | -2.94M | -3M | -3.27M |
| Interest Income | 316K | 389K | 202K | 2.63M | 1.44M | 274K | 137K | 1.71M | 1.79M | 5.33M |
| Interest Expense | 123K | 2.33M | 10.99M | 11.45M | 11.79M | 4.96M | 4.41M | 4.65M | 4.78M | 7.12M |
| Other Income/Expense | 526K | -2.45M | -10.39M | -7.89M | -18.75M | 37.66M | 3.45M | -1.93M | -1.43M | -13.3M |
| Pretax Income | -33.63M▲ 0% | -58.22M▼ 73.1% | -79.88M▼ 37.2% | -65.72M▲ 17.7% | -101.65M▼ 54.7% | 69.47M▲ 168.3% | -23.84M▼ 134.3% | -28.51M▼ 19.6% | 1.85M▲ 106.5% | -12.78M▲ 0% |
| Pretax Margin % | -11841.55% | -49338.14% | -115760.87% | -213.11% | -13287.45% | 86.77% | -118.03% | -99.82% | 2.76% | -10.94% |
| Income Tax | 35K | 384K | -354K | -576K | -428K | 2.21M | -116K | 380K | 340K | 1.68M |
| Effective Tax Rate % | -0.1% | -0.66% | 0.44% | 0.88% | 0.42% | 3.19% | 0.49% | -1.33% | 18.41% | -13.13% |
| Net Income | -33.67M▲ 0% | -58.6M▼ 74.1% | -79.52M▼ 35.7% | -65.14M▲ 18.1% | -101.22M▼ 55.4% | 67.26M▲ 166.4% | -23.72M▼ 135.3% | -28.89M▼ 21.8% | 1.51M▲ 105.2% | -16.49M▲ 0% |
| Net Margin % | -11854.58% | -49664.41% | -115247.83% | -211.24% | -13231.5% | 84% | -117.45% | -101.15% | 2.25% | -14.12% |
| Net Income Growth % | -96.48% | -74.07% | -35.69% | 18.08% | -55.38% | 166.45% | -135.27% | -21.81% | 105.22% | -161.19% |
| Net Income (Continuing) | -33.66M | -55.73M | -79.52M | -65.14M | -101.22M | 67.26M | -23.72M | -28.89M | 1.51M | -14.46M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.25▲ 0% | -1.88▼ 50.4% | -2.55▼ 35.6% | -1.76▲ 31.0% | -2.60▼ 47.7% | 1.23▲ 147.3% | -0.48▼ 139.0% | -0.58▼ 20.8% | 0.03▲ 105.2% | -0.33▲ 0% |
| EPS Growth % | -81.16% | -50.4% | -35.64% | 30.98% | -47.73% | 147.31% | -139.02% | -20.83% | 105.17% | -212.82% |
| EPS (Basic) | -1.28 | -1.88 | -2.55 | -1.76 | -2.60 | 1.50 | -0.48 | -0.58 | 0.03 | - |
| Diluted Shares Outstanding | 26.85M | 31.17M | 31.17M | 36.99M | 38.86M | 55.61M | 49.67M | 49.7M | 50.23M | 49.78M |
| Basic Shares Outstanding | 26.35M | 31.16M | 31.17M | 36.99M | 38.86M | 44.74M | 49.67M | 49.82M | 50.23M | 49.78M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
GNFT Balance Sheet
Genfit S.A. (GNFT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 162M | 283.57M | 218.12M | 290.75M | 184.72M | 268.1M | 158.46M | 113.11M | 92.77M | 155.43M |
| Cash & Short-Term Investments | 152.28M | 273.82M | 207.24M | 276.75M | 171.03M | 258.76M | 140.55M | 77.79M | 81.79M | 107.51M |
| Cash Only | 152.28M | 273.82M | 207.24M | 276.75M | 171.03M | 258.76M | 136M | 77.79M | 81.79M | 107.51M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 4.55M | 0 | 0 | 0 |
| Accounts Receivable | 8.39M | 417K | 395K | 12.03M | 11.92M | 7.24M | 15.91M | 32.71M | 7.56M | 36.88M |
| Days Sales Outstanding | 10.79K | 1.29K | 2.09K | 142.43 | 5.69K | 32.99 | 287.48 | 417.93 | 41.21 | 115.77 |
| Inventory | 14K | 4K | 4K | 4K | 4K | 4K | 4K | 4K | 4K | 4K |
| Days Inventory Outstanding | 2.57 | 0.66 | 0.79 | 8.25 | 7.23 | 9.07 | 5.89 | 4.28 | 4.87 | -0.31 |
| Other Current Assets | 726K | 7.88M | 8.77M | -1K | 0 | 0 | 0 | 0 | 1K | 6.83M |
| Total Non-Current Assets | 4.22M | 9.61M | 11.36M | 19.1M | 13.9M | 13.62M | 57.08M | 60.76M | 58.66M | 61.25M |
| Property, Plant & Equipment | 3.01M | 6.32M | 7.76M | 16.45M | 11.65M | 9.02M | 8.21M | 7.87M | 7.59M | 7.91M |
| Fixed Asset Turnover | 0.09x | 0.02x | 0.01x | 1.87x | 0.07x | 8.88x | 2.46x | 3.63x | 8.82x | 14.86x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 667K | 636K | 795K | 920K | 791K | 174K | 43.96M | 48.76M | 48M | 50.35M |
| Long-Term Investments | 109K | 267K | 770K | 1.73M | 1.46M | 4.43M | 4.91M | 2.82M | 1.88M | 9.6M |
| Other Non-Current Assets | 433K | 1K | 2.03M | -1K | -11.95M | 3K | -55.78M | 1.3M | 1.18M | 3.28M |
| Total Assets | 166.21M▲ 0% | 293.18M▲ 76.4% | 229.48M▼ 21.7% | 309.85M▲ 35.0% | 198.61M▼ 35.9% | 281.72M▲ 41.8% | 215.54M▼ 23.5% | 173.87M▼ 19.3% | 151.42M▼ 12.9% | 216.68M▲ 0% |
| Asset Turnover | 0.00x | 0.00x | 0.00x | 0.10x | 0.00x | 0.28x | 0.09x | 0.16x | 0.44x | 0.63x |
| Asset Growth % | 139.99% | 76.39% | -21.73% | 35.03% | -35.9% | 41.84% | -23.49% | -19.33% | -12.91% | -20.55% |
| Total Current Liabilities | 17.56M | 27.11M | 39.25M | 43.49M | 31.07M | 62.84M | 39.37M | 38.48M | 75.16M | 41.58M |
| Accounts Payable | 13.34M | 19.05M | 32.65M | 32.75M | 20.34M | 12.3M | 8.61M | 10.45M | 18.39M | 14.01M |
| Days Payables Outstanding | 2.45K | 3.12K | 6.43K | 67.54K | 36.75K | 27.89K | 12.68K | 11.18K | 22.37K | -986.46 |
| Short-Term Debt | 1.17M | 2.74M | 2.64M | 2.42M | 2.26M | 1.1M | 4.05M | 6.85M | 55.44M | 16.46M |
| Deferred Revenue (Current) | 1K | 1K | 1K | 139K | 124K | 14.3M | 14.48M | 11.69M | 0 | 11.69M |
| Other Current Liabilities | 2.97M | 378K | 112K | 5.56M | 1.03M | 313K | 61K | 40K | 39K | 342K |
| Current Ratio | 9.22x | 10.46x | 5.56x | 6.68x | 5.95x | 4.27x | 4.02x | 2.94x | 1.23x | 1.23x |
| Quick Ratio | 9.22x | 10.46x | 5.56x | 6.68x | 5.95x | 4.27x | 4.02x | 2.94x | 1.23x | 1.23x |
| Cash Conversion Cycle | 8.34K | -1.83K | -4.34K | -67.39K | -31.05K | -27.85K | -12.38K | -10.76K | -22.32K | 1.1K |
| Total Non-Current Liabilities | 5.86M | 161.85M | 169.29M | 182.29M | 183.71M | 99.79M | 81.64M | 67.44M | 7.04M | 122.64M |
| Long-Term Debt | 4.7M | 160.05M | 165.05M | 168.91M | 173.3M | 66.07M | 64.67M | 57.45M | 1.64M | 117.8M |
| Capital Lease Obligations | 307K | 1.47M | 1.38M | 10.17M | 8.05M | 5.98M | 5.53M | 4.81M | 3.92M | 16.68M |
| Deferred Tax Liabilities | 0 | 321K | 1.77M | 1.19M | 767K | 602K | 510K | 455K | 145K | 600K |
| Other Non-Current Liabilities | 849K | 937K | 1.08M | 2.02M | 1.6M | 1.32M | 1.23M | 978K | 1.34M | 4.88M |
| Total Liabilities | 23.42M | 188.95M | 208.54M | 225.79M | 214.78M | 162.62M | 121.01M | 105.92M | 82.2M | 164.21M |
| Total Debt | 6.25M | 163.75M | 169.59M | 183.62M | 185.69M | 74.23M | 75.28M | 70.18M | 62.13M | 138.91M |
| Net Debt | -146.03M | -110.07M | -37.66M | -93.13M | 14.66M | -184.52M | -60.73M | -7.61M | -19.66M | 31.4M |
| Debt / Equity | 0.04x | 1.57x | 8.10x | 2.18x | - | 0.62x | 0.80x | 1.03x | 0.90x | 0.90x |
| Debt / EBITDA | - | - | - | - | - | 2.15x | - | - | 12.41x | 35.72x |
| Net Debt / EBITDA | - | - | - | - | - | -5.34x | - | - | -3.93x | -3.93x |
| Interest Coverage | -277.71x | -24.31x | -6.33x | -4.74x | -6.50x | 6.49x | -6.27x | -5.14x | 1.38x | -0.67x |
| Total Equity | 142.8M▲ 0% | 104.23M▼ 27.0% | 20.94M▼ 79.9% | 84.06M▲ 301.5% | -16.16M▼ 119.2% | 119.1M▲ 836.9% | 94.53M▼ 20.6% | 67.95M▼ 28.1% | 69.22M▲ 1.9% | 52.47M▲ 0% |
| Equity Growth % | 157.68% | -27.01% | -79.91% | 301.48% | -119.23% | 836.9% | -20.63% | -28.12% | 1.87% | -41.7% |
| Book Value per Share | 5.32 | 3.34 | 0.67 | 2.27 | -0.42 | 2.14 | 1.90 | 1.37 | 1.38 | 1.05 |
| Total Shareholders' Equity | 142.8M | 104.23M | 20.94M | 84.06M | -16.16M | 119.1M | 94.53M | 67.95M | 69.22M | 52.47M |
| Common Stock | 7.79M | 7.79M | 7.8M | 9.71M | 9.72M | 12.45M | 12.46M | 12.46M | 12.5M | 12.5M |
| Retained Earnings | -102.32M | -161.13M | -238.42M | -303.48M | -404.85M | -337.82M | -361.27M | -389.79M | -390.57M | -399.39M |
| Treasury Stock | 0 | -127K | 0 | 0 | 0 | 0 | 0 | -970K | 0 | -1.1M |
| Accumulated OCI | 21K | -8K | 6K | 14K | -92K | 22K | -1.34M | 996K | 347K | 185K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GNFT Cash Flow Statement
Genfit S.A. (GNFT) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -27.23M | -49.86M | -56.08M | -47.68M | -96.37M | 99.92M | -72.64M | -55.43M | 15.55M | 15.2M |
| Operating CF Margin % | -9586.62% | -42250.85% | -81276.81% | -154.61% | -12597.52% | 124.79% | -359.68% | -194.05% | 23.21% | - |
| Operating CF Growth % | -83.09% | -83.12% | -12.49% | 14.98% | -102.12% | 203.68% | -172.7% | 23.69% | 128.05% | 60.22% |
| Net Income | -33.67M | -58.6M | -79.52M | -65.14M | -101.22M | 67.26M | -23.72M | -28.89M | 1.51M | -16.49M |
| Depreciation & Amortization | 816K | 1.41M | 1.82M | 5.41M | 3.56M | 2.74M | 1.83M | 1.65M | 1.72M | 3.44M |
| Stock-Based Compensation | 11K | 278K | 787K | 1.66M | 1.24M | 470K | 245K | 578K | 0 | 880K |
| Deferred Taxes | 35K | 384K | -354K | -576K | -428K | 2.21M | -116K | 380K | 0 | 0 |
| Other Non-Cash Items | -321K | 1.39M | 10.5M | 11.33M | 11.61M | -32.45M | 3.91M | -1.33M | 3.88M | 24.7M |
| Working Capital Changes | 5.9M | 5.28M | 10.33M | -356K | -11.13M | 59.68M | -54.79M | -27.82M | 8.43M | -36.39M |
| Change in Receivables | -2.94M | -2.11M | -724K | -1.64M | 318K | 4.34M | -8.56M | -17.42M | 23.96M | -26.43M |
| Change in Inventory | 14K | 10K | 0 | 0 | 0 | 0 | 0 | 17.42M | 0 | 0 |
| Change in Payables | 8.83M | 7.38M | 11.06M | 1.28M | -11.45M | 55.34M | -46.23M | -10.4M | -15.53M | -5.92M |
| Cash from Investing | -2.09M | -2.95M | -3.99M | 327K | -966K | -3.38M | -46.27M | 2.23M | -1.04M | -4.71M |
| Capital Expenditures | -2.04M | -2.8M | -2.94M | -2.03M | -900K | -537K | 0 | -2.49M | -979K | -2.45M |
| CapEx % of Revenue | 716.9% | 2372.88% | 4257.97% | 6.58% | 117.65% | 0.67% | - | 8.71% | 1.46% | - |
| Acquisitions | 0 | 15K | 3K | 2.52M | 0 | 309K | -41.52M | 0 | 0 | 2K |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 1K | -148K | 2K | 2.52M | 0 | 308K | 271K | 172K | 80K | -1.94M |
| Cash from Financing | 121.48M | 174.35M | -6.51M | 116.86M | -8.26M | -8.92M | -3.79M | -5.1M | -10.57M | 45.19M |
| Debt Issued (Net) | 466K | 175.68M | -200K | -1.88M | -1.94M | -35.05M | -1.75M | -4.61M | -9.17M | 53.15M |
| Equity Issued (Net) | 121.01M | 0 | 0 | 126.49M | 7K | 27.97M | 5K | 0 | 61K | -3.3M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 7K | -1.33M | -6.31M | -7.74M | -6.32M | -1.83M | -2.04M | -493K | -1.46M | -4.66M |
| Net Change in Cash | 92.17M▲ 0% | 121.54M▲ 31.9% | -66.58M▼ 154.8% | 69.51M▲ 204.4% | -105.72M▼ 252.1% | 87.73M▲ 183.0% | -122.75M▼ 239.9% | -58.21M▲ 52.6% | 4M▲ 106.9% | -8.31M▲ 0% |
| Free Cash Flow | -29.26M▲ 0% | -52.66M▼ 79.9% | -59.02M▼ 12.1% | -49.71M▲ 15.8% | -97.27M▼ 95.7% | 99.38M▲ 202.2% | -72.64M▼ 173.1% | -57.92M▲ 20.3% | 14.22M▲ 124.6% | -47.17M▲ 0% |
| FCF Margin % | -10303.52% | -44623.73% | -85534.78% | -161.19% | -12715.16% | 124.12% | -359.68% | -202.76% | 21.22% | -40.38% |
| FCF Growth % | -86.86% | -79.95% | -12.08% | 15.77% | -95.68% | 202.17% | -173.09% | 20.27% | 124.55% | -299.15% |
| FCF per Share | -1.09 | -1.69 | -1.89 | -1.34 | -2.50 | 1.79 | -1.46 | -1.17 | 0.28 | 0.28 |
| FCF Conversion (FCF/Net Income) | 0.81x | 0.85x | 0.71x | 0.73x | 0.95x | 1.49x | 3.06x | 1.92x | 10.32x | 2.86x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 530K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GNFT Key Ratios
Genfit S.A. (GNFT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -33.97% | -47.45% | -127.06% | -124.08% | -298.13% | 130.68% | -22.21% | -35.57% | 2.2% | -22.98% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | -60.55% | -42.35% | 4.48% | 4.48% |
| Gross Margin | -598.94% | -1788.98% | -2586.96% | 99.43% | 73.59% | 99.8% | 98.77% | 98.81% | 99.55% | 104.85% |
| Net Margin | -11854.58% | -49664.41% | -115247.83% | -211.24% | -13231.5% | 84% | -117.45% | -101.15% | 2.25% | -14.12% |
| Debt / Equity | 0.04x | 1.57x | 8.10x | 2.18x | - | 0.62x | 0.80x | 1.03x | 0.90x | 0.90x |
| Interest Coverage | -277.71x | -24.31x | -6.33x | -4.74x | -6.50x | 6.49x | -6.27x | -5.14x | 1.38x | -0.67x |
| FCF Conversion | 0.81x | 0.85x | 0.71x | 0.73x | 0.95x | 1.49x | 3.06x | 1.92x | 10.32x | 2.86x |
| Revenue Growth | -46.11% | -58.45% | -41.53% | 44594.2% | -97.52% | 10366.54% | -74.78% | 41.45% | 134.56% | 9.75% |
GNFT Frequently Asked Questions
Genfit S.A. (GNFT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Genfit S.A. (GNFT) reported $116.8M in revenue for fiscal year 2024. This represents a 841% increase from $12.4M in 2004.
Genfit S.A. (GNFT) grew revenue by 134.6% over the past year. This is strong growth.
Genfit S.A. (GNFT) reported a net loss of $16.5M for fiscal year 2024.
Dividend & Returns
Genfit S.A. (GNFT) has a return on equity (ROE) of 2.2%. This is below average, suggesting room for improvement.
Genfit S.A. (GNFT) had negative free cash flow of $47.2M in fiscal year 2024, likely due to heavy capital investments.
Explore More GNFT
Genfit S.A. (GNFT) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates